Ivonescimab (ivonescimab Injection / 依达方® In China)

Type:Humanized bispecific monoclonal antibody targeting PD-1 and VEGF-A

Mechanism:Cooperative binding — PD-1 blockade enhances immune anti-tumor activity; VEGF blockade inhibits angiogenesis; synergistic design improves target affinity and potency

Dosage/Administration (from clinical trials and approvals):

Typically 20 mg/kg intravenously every 3 weeks (Q3W) as monotherapy or in combination regimens
In combinations: Often paired with chemotherapy (e.g., carboplatin + pemetrexed)

CAS Number:2428381-53-5

Form:Injectable (sterile solution for IV infusion)

Half-life:Approximately 5–7.3 days (dose-dependent, from Phase I data)

Common indications studied:Advanced NSCLC (PD-L1-positive, EGFR-mutated, squamous/non-squamous), other solid tumors (e.g., head and neck, colorectal, etc., in ongoing trials)

Key clinical highlights:Superior PFS in head-to-head vs. pembrolizumab (e.g., 11.1 vs. 5.8 months in HARMONi-2); OS benefits in some settings (e.g., HR 0.74–0.777 in certain analyses)

Safety notes:Common adverse events include proteinuria, hypertension, elevated liver enzymes, anemia; generally manageable, with no new major signals beyond VEGF/PD-1 class effects